Browsing: South Africa

Kenya Airways (KQ) and South African Airways (SAA) have signed a codeshare agreement that opens more destinations for seamless travel…

Zambia is Africa’s largest copper producer, which is one of the reasons it has one of the strongest currencies on the continent. The country possesses abundant natural resources, and because copper is the most prevalent metal, copper mining is carried out on a massive scale. This provides Zambia with a significant rise in foreign currency earnings from the sale of metals to other countries.

Bscholarly notes that the value of a currency is significant because it determines the economic performance of a country. This has a direct impact on a currency’s demand on the global market. Exchange rates compare one currency to another and provide an overview of a currency’s strength in the global marketplace. According to financial analysts, factors like interest rates, economic policies, and stability determine the strength of any currency.

Mining liberalization, a debt restructuring programme following default on debt repayments in 2020, and high commodity prices have also had a positive impact on the performance of the local currency.

The African Development Bank (AfDB)’s Board of Directors has approved the establishment of the African Pharmaceutical Technology Foundation, a new ground-breaking institution that will significantly enhance Africa’s access to the technologies that underpin the manufacture of medicines, vaccines, and other pharmaceutical products.

Africa has great potential for drug discovery. The continent has natural resources, indigenous knowledge, and human capacity

AfDB Group President, Dr. Akinwumi Adesina said: “This is a great development for Africa. Africa must have a health defence system, which must include three major areas: revamping Africa’s pharmaceutical industry, building Africa’s vaccine manufacturing capacity, and building Africa’s quality healthcare infrastructure.”

The World Trade Organization and the World Health Organization, respectively, also welcomed and lauded the AfDB’s decision to establish the African Pharmaceutical Technology Foundation.

The Entebbe airport stands to transform Uganda’s movement over time as it advances to become an oil economy alongside Tanzania.

South Africa, one of the wealthiest countries, has the largest road network, 750,000kms, while Tanzania, East Africa’s competitive economy, has more than 86,000km of roads.

In the current economic scenario, where uncertainty brought by economic shocks from the pandemic and political tensions force nations to expand their horizon of influence, the past years have shown why African infrastructures must be robust and conducive to enhancing value creation.

Whoever moves fast and swiftly dominates the economic conversation. South Africa, Kenya, Namibia and Nigeria are among the top African nations with more robust economies.

Reliable and affordable telecom services have never been more vital to our national economic and social resilience. That is why,…

Banking industry in South Africa staged a strong come back in 2021 in report by PWC. Banks enjoyed supportive credit…

Platinum mining is where Loucas Pouroulis, the chairman of mining outfit Tharisa PLC made and then lost money and then…

Tharisa PLC will be the latest foreign platinum mining firm to enter and invest in the Great Dyke in Zimbabwe.…

Zimbabwe’s platinum resources are out of reach for most of the investing public. Platinum is one the largest generators of…

mRNA-1644 utilizes Moderna’s messenger RNA (mRNA) technology to deliver a specific class of B cells needed to develop broadly neutralizing antibodies (bnAbs) to fight HIV infection. Inducing bnAbs is considered the primary goal of an HIV vaccine, and this requires B-cell activation.

The primary trial endpoints are safety and immunogenicity. The IAVI-sponsored clinical trial, IAVI G003, will test the safety and efficacy of vaccination with the HIV immunogen eOD-GT8 60mer, delivered via Moderna’s mRNA platform. eOD-GT8 60mer was developed by IAVI and Scripps Research teams and was initially tested in phase 1 clinical trial IAVI G001.

According to Contagion Live, IAVI G003 is expected to enroll 18 healthy, HIV-negative adults. The participants will receive 2 doses of eOD-GT8 60mer mRNA, which contains a portion of the viral sequence but cannot cause HIV infection. They will be monitored for safety for 6 months after their second dose, and their immune responses will be examined in molecular detail to evaluate whether the target was achieved.